Utility of GLP-1R agonists in diabetes requires long term study

What is the clinical relevance to diabetes treatment of the meta-analysis of the effects of glucagon-like peptide-1 receptor (GLP-1R) agonists on weight loss, given that it included mostly short term studies? Contrary to what was stated in the companion editorial, 2 GLP-1R agonists seem to increase...

Full description

Saved in:
Bibliographic Details
Published in:BMJ 2012-02, Vol.344 (feb28 2), p.e1451; author reply e1459-e1451
Main Author: de Oliveira, Jose Mario Franco
Format: Article
Language:English
Subjects:
Anti-Obesity Agents - therapeutic use
Diabetes
Diabetes mellitus
Glucagon-Like Peptide 1 - analogs & derivatives
Humans
Hypoglycemic Agents - therapeutic use
Overweight - drug therapy
Peptides
Peptides - therapeutic use
Receptors, Glucagon - agonists
Thyroid gland
Venoms - therapeutic use
Weight Loss - drug effects
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b294t-317cc1b3100f8cd4ea3187d20bd70d87db7e7d26a9cfa2c7094d41ed0fe63c153
cites
container_end_page e1451
container_issue feb28 2
container_start_page e1451; author reply e1459
container_title BMJ
container_volume 344
creator de Oliveira, Jose Mario Franco
description What is the clinical relevance to diabetes treatment of the meta-analysis of the effects of glucagon-like peptide-1 receptor (GLP-1R) agonists on weight loss, given that it included mostly short term studies? Contrary to what was stated in the companion editorial, 2 GLP-1R agonists seem to increase the incidence of pancreatitis and pancreatic and thyroid cancers. 3 Only long term prospective comparative randomised trials against established drug treatment of diabetes will determine their effectiveness and safety in diabetes.
doi_str_mv 10.1136/bmj.e1451
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_925717121</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>925717121</sourcerecordid><originalsourceid>FETCH-LOGICAL-b294t-317cc1b3100f8cd4ea3187d20bd70d87db7e7d26a9cfa2c7094d41ed0fe63c153</originalsourceid><addsrcrecordid>eNp1kE1Lw0AQhhdRbKk9-AckoCAeUneyyW72JFK0CsWP0va6bLKbkpoPu5uA_fduTe1B8DTvMA8zw4PQOeARAKG3SbkeaQgjOEJ9CGnsRzEhx6iPecT9GEjcQ0Nr1xjjgLCY0-gU9QIXQ47DPrpbNHmRN1uvzrzJ9M2HmSdXdZXbxnp55alcJrrR1jN60-bGhaKuVl6jTenZplXbM3SSycLq4b4O0OLxYT5-8qevk-fx_dRPAh42PgGWppAQwDiLUxVqSSBmKsCJYli5lDDtWip5mskgZZiHKgStcKYpSSEiA3Td7f009abVthFlblNdFLLSdWsFDyIGDAJw5OUfcl23pnLPCeBOU4wppY666ajU1NYanYlPk5fSbAVgsfMqnFfx49WxF_uNbVJqdSB_LTrA7wCnTX8d5tJ8CMoIi8TLciyC2XLO3yESS8dfdfzuxv93vwGQBowu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1945180666</pqid></control><display><type>article</type><title>Utility of GLP-1R agonists in diabetes requires long term study</title><source>BMJ journals single titles</source><source>JSTOR</source><creator>de Oliveira, Jose Mario Franco</creator><creatorcontrib>de Oliveira, Jose Mario Franco</creatorcontrib><description>What is the clinical relevance to diabetes treatment of the meta-analysis of the effects of glucagon-like peptide-1 receptor (GLP-1R) agonists on weight loss, given that it included mostly short term studies? Contrary to what was stated in the companion editorial, 2 GLP-1R agonists seem to increase the incidence of pancreatitis and pancreatic and thyroid cancers. 3 Only long term prospective comparative randomised trials against established drug treatment of diabetes will determine their effectiveness and safety in diabetes.</description><identifier>ISSN: 0959-8138</identifier><identifier>EISSN: 1468-5833</identifier><identifier>EISSN: 1756-1833</identifier><identifier>DOI: 10.1136/bmj.e1451</identifier><identifier>PMID: 22374904</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>Anti-Obesity Agents - therapeutic use ; Diabetes ; Diabetes mellitus ; Glucagon-Like Peptide 1 - analogs &amp; derivatives ; Humans ; Hypoglycemic Agents - therapeutic use ; Overweight - drug therapy ; Peptides ; Peptides - therapeutic use ; Receptors, Glucagon - agonists ; Thyroid gland ; Venoms - therapeutic use ; Weight Loss - drug effects</subject><ispartof>BMJ, 2012-02, Vol.344 (feb28 2), p.e1451; author reply e1459-e1451</ispartof><rights>BMJ Publishing Group Ltd 2012</rights><rights>Copyright: 2012 © BMJ Publishing Group Ltd 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b294t-317cc1b3100f8cd4ea3187d20bd70d87db7e7d26a9cfa2c7094d41ed0fe63c153</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://bmj.com/content/344/bmj.e1451.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://bmj.com/content/344/bmj.e1451.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>112,113,314,780,784,3194,27924,27925,77594,77595</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22374904$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de Oliveira, Jose Mario Franco</creatorcontrib><title>Utility of GLP-1R agonists in diabetes requires long term study</title><title>BMJ</title><addtitle>BMJ</addtitle><description>What is the clinical relevance to diabetes treatment of the meta-analysis of the effects of glucagon-like peptide-1 receptor (GLP-1R) agonists on weight loss, given that it included mostly short term studies? Contrary to what was stated in the companion editorial, 2 GLP-1R agonists seem to increase the incidence of pancreatitis and pancreatic and thyroid cancers. 3 Only long term prospective comparative randomised trials against established drug treatment of diabetes will determine their effectiveness and safety in diabetes.</description><subject>Anti-Obesity Agents - therapeutic use</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Glucagon-Like Peptide 1 - analogs &amp; derivatives</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Overweight - drug therapy</subject><subject>Peptides</subject><subject>Peptides - therapeutic use</subject><subject>Receptors, Glucagon - agonists</subject><subject>Thyroid gland</subject><subject>Venoms - therapeutic use</subject><subject>Weight Loss - drug effects</subject><issn>0959-8138</issn><issn>1468-5833</issn><issn>1756-1833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp1kE1Lw0AQhhdRbKk9-AckoCAeUneyyW72JFK0CsWP0va6bLKbkpoPu5uA_fduTe1B8DTvMA8zw4PQOeARAKG3SbkeaQgjOEJ9CGnsRzEhx6iPecT9GEjcQ0Nr1xjjgLCY0-gU9QIXQ47DPrpbNHmRN1uvzrzJ9M2HmSdXdZXbxnp55alcJrrR1jN60-bGhaKuVl6jTenZplXbM3SSycLq4b4O0OLxYT5-8qevk-fx_dRPAh42PgGWppAQwDiLUxVqSSBmKsCJYli5lDDtWip5mskgZZiHKgStcKYpSSEiA3Td7f009abVthFlblNdFLLSdWsFDyIGDAJw5OUfcl23pnLPCeBOU4wppY666ajU1NYanYlPk5fSbAVgsfMqnFfx49WxF_uNbVJqdSB_LTrA7wCnTX8d5tJ8CMoIi8TLciyC2XLO3yESS8dfdfzuxv93vwGQBowu</recordid><startdate>20120228</startdate><enddate>20120228</enddate><creator>de Oliveira, Jose Mario Franco</creator><general>British Medical Journal Publishing Group</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20120228</creationdate><title>Utility of GLP-1R agonists in diabetes requires long term study</title><author>de Oliveira, Jose Mario Franco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b294t-317cc1b3100f8cd4ea3187d20bd70d87db7e7d26a9cfa2c7094d41ed0fe63c153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Anti-Obesity Agents - therapeutic use</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Glucagon-Like Peptide 1 - analogs &amp; derivatives</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Overweight - drug therapy</topic><topic>Peptides</topic><topic>Peptides - therapeutic use</topic><topic>Receptors, Glucagon - agonists</topic><topic>Thyroid gland</topic><topic>Venoms - therapeutic use</topic><topic>Weight Loss - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Oliveira, Jose Mario Franco</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest research library</collection><collection>Science Database</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>BMJ</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Oliveira, Jose Mario Franco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Utility of GLP-1R agonists in diabetes requires long term study</atitle><jtitle>BMJ</jtitle><addtitle>BMJ</addtitle><date>2012-02-28</date><risdate>2012</risdate><volume>344</volume><issue>feb28 2</issue><spage>e1451; author reply e1459</spage><epage>e1451</epage><pages>e1451; author reply e1459-e1451</pages><issn>0959-8138</issn><eissn>1468-5833</eissn><eissn>1756-1833</eissn><abstract>What is the clinical relevance to diabetes treatment of the meta-analysis of the effects of glucagon-like peptide-1 receptor (GLP-1R) agonists on weight loss, given that it included mostly short term studies? Contrary to what was stated in the companion editorial, 2 GLP-1R agonists seem to increase the incidence of pancreatitis and pancreatic and thyroid cancers. 3 Only long term prospective comparative randomised trials against established drug treatment of diabetes will determine their effectiveness and safety in diabetes.</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>22374904</pmid><doi>10.1136/bmj.e1451</doi></addata></record>
fulltext fulltext
identifier ISSN: 0959-8138
ispartof BMJ, 2012-02, Vol.344 (feb28 2), p.e1451; author reply e1459-e1451
issn 0959-8138
1468-5833
1756-1833
language eng
recordid cdi_proquest_miscellaneous_925717121
source BMJ journals single titles; JSTOR
subjects Anti-Obesity Agents - therapeutic use
Diabetes
Diabetes mellitus
Glucagon-Like Peptide 1 - analogs & derivatives
Humans
Hypoglycemic Agents - therapeutic use
Overweight - drug therapy
Peptides
Peptides - therapeutic use
Receptors, Glucagon - agonists
Thyroid gland
Venoms - therapeutic use
Weight Loss - drug effects
title Utility of GLP-1R agonists in diabetes requires long term study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T13%3A50%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Utility%20of%20GLP-1R%20agonists%20in%20diabetes%20requires%20long%20term%20study&rft.jtitle=BMJ&rft.au=de%20Oliveira,%20Jose%20Mario%20Franco&rft.date=2012-02-28&rft.volume=344&rft.issue=feb28%202&rft.spage=e1451;%20author%20reply%20e1459&rft.epage=e1451&rft.pages=e1451;%20author%20reply%20e1459-e1451&rft.issn=0959-8138&rft.eissn=1468-5833&rft_id=info:doi/10.1136/bmj.e1451&rft_dat=%3Cproquest_cross%3E925717121%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b294t-317cc1b3100f8cd4ea3187d20bd70d87db7e7d26a9cfa2c7094d41ed0fe63c153%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1945180666&rft_id=info:pmid/22374904&rfr_iscdi=true